Analyst Kallum Titchmarsh of Morgan Stanley maintained a Hold rating on Charles River Labs, retaining the price target of $185.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kallum Titchmarsh has given his Hold rating due to a combination of factors related to Charles River’s portfolio reshaping and the associated financial trade-offs. The planned sale of the CDMO, Cell Solutions, and certain European Discovery Services assets simplifies the business mix and should enhance the company’s margin profile, but it also meaningfully reduces future reported revenue.
While the divestitures help Charles River exit slower or more challenging areas and hand off earlier-stage, innovative assets to strategic buyers, they also drive a step-down in 2026 growth expectations. Management now anticipates a mid-single-digit decline in reported revenue and a small decline in organic revenue, which tempers the upside case and supports a more balanced risk-reward, consistent with a Hold stance.
In another report released yesterday, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $167.00 price target.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRL in relation to earlier this year.